Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lung Neoplasms 76Leukemia, Myeloid, Acute 70Prostatic Neoplasms 67Neoplasm Metastasis 56Carcinoma, Non-Small-Cell Lung 56Breast Neoplasms 45Multiple Myeloma 44Colorectal Neoplasms 40Pancreatic Neoplasms 36Myelodysplastic Syndromes 35Carcinoma, Renal Cell 33Ovarian Neoplasms 31Leukemia, Lymphocytic, Chronic, B-Cell 30Melanoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Glioblastoma 27Triple Negative Breast Neoplasms 26Lymphoma, Large B-Cell, Diffuse 26Urinary Bladder Neoplasms 24Lymphoma 23Burkitt Lymphoma 22Squamous Cell Carcinoma of Head and Neck 21Glioma 20Fallopian Tube Neoplasms 20Carcinoma, Hepatocellular 18Mouth Neoplasms 17Leukemia, Biphenotypic, Acute 17Brain Neoplasms 17Sarcoma 16Oropharyngeal Neoplasms 16

Interventions

Radiosurgery 4Magnetic Resonance Spectroscopy 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Salicylic Acid 1Receptors, Bombesin 1Radium-223 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Prostate Adenocarcinoma × Specimen Handling × Clear all
NCT06022822 2026-05-13

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
90 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT06499870 2025-10-21

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡